<?xml version="1.0" encoding="UTF-8"?>
<ref id="B140-vaccines-07-00053">
 <label>140.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wilson</surname>
    <given-names>J.R.</given-names>
   </name>
   <name>
    <surname>Belser</surname>
    <given-names>J.A.</given-names>
   </name>
   <name>
    <surname>DaSilva</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Gansebom</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bai</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Stark</surname>
    <given-names>T.J.</given-names>
   </name>
   <name>
    <surname>Chang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Carney</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge</article-title>
  <source>Virology</source>
  <year>2017</year>
  <volume>511</volume>
  <fpage>214</fpage>
  <lpage>221</lpage>
  <pub-id pub-id-type="doi">10.1016/j.virol.2017.08.016</pub-id>
  <pub-id pub-id-type="pmid">28888111</pub-id>
 </element-citation>
</ref>
